Detalhe da pesquisa
1.
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
Blood
; 143(7): 592-596, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048557
2.
Update and European consensus on a patient-centered core outcome set for multiple myeloma in clinical practice and research.
Haematologica
; 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38299690
3.
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.
Blood
; 137(22): 3027-3036, 2021 06 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33739404
4.
High levels of hypusinated eIF5A in leiomyoma and leiomyosarcoma pathologies: a possible novel therapeutic target.
Reprod Biomed Online
; 47(1): 15-25, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37137790
5.
Control of the eIF4E activity: structural insights and pharmacological implications.
Cell Mol Life Sci
; 78(21-22): 6869-6885, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34541613
6.
Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?
Int J Mol Sci
; 23(24)2022 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36555520
7.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 22(12): 1705-1720, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34774221
8.
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma.
Haematologica
; 106(8): 2054-2065, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33792221
9.
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.
Ann Hematol
; 100(2): 437-443, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33392702
10.
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
Haematologica
; 105(7): 1937-1947, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31582542
11.
Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True.
Int J Mol Sci
; 21(21)2020 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33139668
12.
Crystal structure of archaeal IF5A-DHS complex reveals insights into the hypusination mechanism.
Structure
; 2024 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38582076
13.
Gentle yet effective combination therapy with novel agents in elderly multiple myeloma patients.
Br J Haematol
; 182(2): 165-167, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29732537
14.
Multi-fuel driven Janus micromotors.
Small
; 9(3): 467-71, 2013 Feb 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-23055445
15.
Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop.
Clin Lymphoma Myeloma Leuk
; 23(6): 413-419, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37055346
16.
Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myeloma.
medRxiv
; 2023 Dec 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38106151
17.
Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.
Exp Hematol Oncol
; 12(1): 71, 2023 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37563685
18.
SARS-CoV-2 multi-variant rapid detector based on graphene transistor functionalized with an engineered dimeric ACE2 receptor.
Nano Today
; 48: 101729, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36536857
19.
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing.
EClinicalMedicine
; 60: 102016, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37396800
20.
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial.
EClinicalMedicine
; 60: 102017, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37396807